Metronidazole use in obstetrics and gynecology: A review

Marilyn Olson Robbie, Richard L Sweet

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.

Original languageEnglish (US)
Pages (from-to)865-881
Number of pages17
JournalAmerican Journal of Obstetrics and Gynecology
Volume145
Issue number7
StatePublished - Apr 1 1983

Fingerprint

Metronidazole
Gynecology
Obstetrics
Antitrichomonal Agents
Reproductive Tract Infections
Giardiasis
Bacterial Vaginosis
Amebiasis
Pharmacokinetics
Infection

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

Metronidazole use in obstetrics and gynecology : A review. / Robbie, Marilyn Olson; Sweet, Richard L.

In: American Journal of Obstetrics and Gynecology, Vol. 145, No. 7, 01.04.1983, p. 865-881.

Research output: Contribution to journalArticle

@article{3394d3f5adc54acb8719179e0b824ac8,
title = "Metronidazole use in obstetrics and gynecology: A review",
abstract = "Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.",
author = "Robbie, {Marilyn Olson} and Sweet, {Richard L}",
year = "1983",
month = "4",
day = "1",
language = "English (US)",
volume = "145",
pages = "865--881",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "7",

}

TY - JOUR

T1 - Metronidazole use in obstetrics and gynecology

T2 - A review

AU - Robbie, Marilyn Olson

AU - Sweet, Richard L

PY - 1983/4/1

Y1 - 1983/4/1

N2 - Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.

AB - Since metronidazole's introduction in 1960 as an effective antitrichomonal agent, its use has extended to the treatment of amebiasis, giardiasis, nonspecific vaginitis, and anaerobic infections, including upper genital tract infections. It is also being explored as a prophylactic agent in numerous surgical procedures. Recent introduction of an intravenous form has further facilitated its expanded use. This review examines the mode of action and pharmacokinetics of metronidazole and discusses evidence concerning the question of mutagenicity and carcinogenicity. Current uses of metronidazole are discussed, with the potential problem of bacterial inactivation/resistance explored. Finally, recommendations are made for the use of metronidazole in obstetrics and gynecology, with an emphasis on caution with respect to potential problems, which remain unanswered.

UR - http://www.scopus.com/inward/record.url?scp=0020646991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020646991&partnerID=8YFLogxK

M3 - Article

C2 - 6340508

AN - SCOPUS:0020646991

VL - 145

SP - 865

EP - 881

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 7

ER -